Research ExplorerPublicationsCytogenetics and long-term survival of patients with refract...

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

Standard

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. / Dimopoulos, Meletios A; Weisel, Katja C; Song, Kevin W; Delforge, Michel; Karlin, Lionel; Goldschmidt, Hartmut; Moreau, Philippe; Banos, Anne; Oriol, Albert; Garderet, Laurent; Cavo, Michele; Ivanova, Valentina; Alegre, Adrian; Martinez-Lopez, Joaquin; Chen, Christine; Spencer, Andrew; Knop, Stefan; Bahlis, Nizar J; Renner, Christoph; Yu, Xin; Hong, Kevin; Sternas, Lars; Jacques, Christian; Zaki, Mohamed H; San Miguel, Jesus F.

In: HAEMATOLOGICA, Vol. 100, No. 10, 10.2015, p. 1327-33.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Dimopoulos, MA, Weisel, KC, Song, KW, Delforge, M, Karlin, L, Goldschmidt, H, Moreau, P, Banos, A, Oriol, A, Garderet, L, Cavo, M, Ivanova, V, Alegre, A, Martinez-Lopez, J, Chen, C, Spencer, A, Knop, S, Bahlis, NJ, Renner, C, Yu, X, Hong, K, Sternas, L, Jacques, C, Zaki, MH & San Miguel, JF 2015, 'Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone', HAEMATOLOGICA, vol. 100, no. 10, pp. 1327-33. https://doi.org/10.3324/haematol.2014.117077

APA

Dimopoulos, M. A., Weisel, K. C., Song, K. W., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Banos, A., Oriol, A., Garderet, L., Cavo, M., Ivanova, V., Alegre, A., Martinez-Lopez, J., Chen, C., Spencer, A., Knop, S., Bahlis, N. J., Renner, C., ... San Miguel, J. F. (2015). Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. HAEMATOLOGICA, 100(10), 1327-33. https://doi.org/10.3324/haematol.2014.117077

Vancouver

Dimopoulos MA, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H et al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. HAEMATOLOGICA. 2015 Oct;100(10):1327-33. https://doi.org/10.3324/haematol.2014.117077

Bibtex

@article{48512885591d4e7fb37955aef4d82454,
title = "Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone",
abstract = "Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among patients in whom bortezomib and lenalidomide treatment had failed. At an updated median follow-up of 15.4 months, the progression-free survival was 4.0 versus 1.9 months (HR, 0.50; P<0.001), and median overall survival was 13.1 versus 8.1 months (HR, 0.72; P=0.009). Pomalidomide plus low-dose dexamethasone, compared with high-dose dexamethasone, improved progression-free survival in patients with del(17p) (4.6 versus 1.1 months; HR, 0.34; P <0.001), t(4;14) (2.8 versus 1.9 months; HR, 0.49; P=0.028), and in standard-risk patients (4.2 versus 2.3 months; HR, 0.55; P<0.001). Although the majority of patients treated with high-dose dexamethasone took pomalidomide after discontinuation, the overall survival of patients treated with pomalidomide plus low-dose dexamethasone or high-dose dexamethasone was 12.6 versus 7.7 months (HR, 0.45; P=0.008) in patients with del(17p), 7.5 versus 4.9 months (HR, 1.12; P=0.761) in those with t(4;14), and 14.0 versus 9.0 months (HR, 0.85; P=0.380) in standard-risk subjects. The overall response rate was higher in patients treated with pomalidomide plus low-dose dexamethasone than in those treated with high-dose dexamethasone both among standard-risk patients (35.2% versus 9.7%) and those with del(17p) (31.8% versus 4.3%), whereas it was similar in patients with t(4;14) (15.9% versus 13.3%). The safety of pomalidomide plus low-dose dexamethasone was consistent with initial reports. In conclusion, pomalidomide plus low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma and del(17p) and/or t(4;14). This study is registered at ClinicalTrials.gov as NCT01311687 and with EudraCT as 2010-019820-30. ",
keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Chromosome Aberrations, Dexamethasone, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Recurrence, Thalidomide, Treatment Outcome, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",
author = "Dimopoulos, {Meletios A} and Weisel, {Katja C} and Song, {Kevin W} and Michel Delforge and Lionel Karlin and Hartmut Goldschmidt and Philippe Moreau and Anne Banos and Albert Oriol and Laurent Garderet and Michele Cavo and Valentina Ivanova and Adrian Alegre and Joaquin Martinez-Lopez and Christine Chen and Andrew Spencer and Stefan Knop and Bahlis, {Nizar J} and Christoph Renner and Xin Yu and Kevin Hong and Lars Sternas and Christian Jacques and Zaki, {Mohamed H} and {San Miguel}, {Jesus F}",
note = "Copyright{\textcopyright} Ferrata Storti Foundation.",
year = "2015",
month = oct,
doi = "10.3324/haematol.2014.117077",
language = "English",
volume = "100",
pages = "1327--33",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "10",

}

RIS

TY - JOUR

T1 - Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

AU - Dimopoulos, Meletios A

AU - Weisel, Katja C

AU - Song, Kevin W

AU - Delforge, Michel

AU - Karlin, Lionel

AU - Goldschmidt, Hartmut

AU - Moreau, Philippe

AU - Banos, Anne

AU - Oriol, Albert

AU - Garderet, Laurent

AU - Cavo, Michele

AU - Ivanova, Valentina

AU - Alegre, Adrian

AU - Martinez-Lopez, Joaquin

AU - Chen, Christine

AU - Spencer, Andrew

AU - Knop, Stefan

AU - Bahlis, Nizar J

AU - Renner, Christoph

AU - Yu, Xin

AU - Hong, Kevin

AU - Sternas, Lars

AU - Jacques, Christian

AU - Zaki, Mohamed H

AU - San Miguel, Jesus F

N1 - Copyright© Ferrata Storti Foundation.

PY - 2015/10

Y1 - 2015/10

N2 - Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among patients in whom bortezomib and lenalidomide treatment had failed. At an updated median follow-up of 15.4 months, the progression-free survival was 4.0 versus 1.9 months (HR, 0.50; P<0.001), and median overall survival was 13.1 versus 8.1 months (HR, 0.72; P=0.009). Pomalidomide plus low-dose dexamethasone, compared with high-dose dexamethasone, improved progression-free survival in patients with del(17p) (4.6 versus 1.1 months; HR, 0.34; P <0.001), t(4;14) (2.8 versus 1.9 months; HR, 0.49; P=0.028), and in standard-risk patients (4.2 versus 2.3 months; HR, 0.55; P<0.001). Although the majority of patients treated with high-dose dexamethasone took pomalidomide after discontinuation, the overall survival of patients treated with pomalidomide plus low-dose dexamethasone or high-dose dexamethasone was 12.6 versus 7.7 months (HR, 0.45; P=0.008) in patients with del(17p), 7.5 versus 4.9 months (HR, 1.12; P=0.761) in those with t(4;14), and 14.0 versus 9.0 months (HR, 0.85; P=0.380) in standard-risk subjects. The overall response rate was higher in patients treated with pomalidomide plus low-dose dexamethasone than in those treated with high-dose dexamethasone both among standard-risk patients (35.2% versus 9.7%) and those with del(17p) (31.8% versus 4.3%), whereas it was similar in patients with t(4;14) (15.9% versus 13.3%). The safety of pomalidomide plus low-dose dexamethasone was consistent with initial reports. In conclusion, pomalidomide plus low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma and del(17p) and/or t(4;14). This study is registered at ClinicalTrials.gov as NCT01311687 and with EudraCT as 2010-019820-30.

AB - Patients with refractory or relapsed and refractory multiple myeloma who no longer receive benefit from novel agents have limited treatment options and short expected survival. del(17p) and t(4;14) are correlated with shortened survival. The phase 3 MM-003 trial demonstrated significant progression-free and overall survival benefits from treatment with pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone among patients in whom bortezomib and lenalidomide treatment had failed. At an updated median follow-up of 15.4 months, the progression-free survival was 4.0 versus 1.9 months (HR, 0.50; P<0.001), and median overall survival was 13.1 versus 8.1 months (HR, 0.72; P=0.009). Pomalidomide plus low-dose dexamethasone, compared with high-dose dexamethasone, improved progression-free survival in patients with del(17p) (4.6 versus 1.1 months; HR, 0.34; P <0.001), t(4;14) (2.8 versus 1.9 months; HR, 0.49; P=0.028), and in standard-risk patients (4.2 versus 2.3 months; HR, 0.55; P<0.001). Although the majority of patients treated with high-dose dexamethasone took pomalidomide after discontinuation, the overall survival of patients treated with pomalidomide plus low-dose dexamethasone or high-dose dexamethasone was 12.6 versus 7.7 months (HR, 0.45; P=0.008) in patients with del(17p), 7.5 versus 4.9 months (HR, 1.12; P=0.761) in those with t(4;14), and 14.0 versus 9.0 months (HR, 0.85; P=0.380) in standard-risk subjects. The overall response rate was higher in patients treated with pomalidomide plus low-dose dexamethasone than in those treated with high-dose dexamethasone both among standard-risk patients (35.2% versus 9.7%) and those with del(17p) (31.8% versus 4.3%), whereas it was similar in patients with t(4;14) (15.9% versus 13.3%). The safety of pomalidomide plus low-dose dexamethasone was consistent with initial reports. In conclusion, pomalidomide plus low-dose dexamethasone is efficacious in patients with relapsed/refractory multiple myeloma and del(17p) and/or t(4;14). This study is registered at ClinicalTrials.gov as NCT01311687 and with EudraCT as 2010-019820-30.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Chromosome Aberrations

KW - Dexamethasone

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Neoplasm Staging

KW - Prognosis

KW - Recurrence

KW - Thalidomide

KW - Treatment Outcome

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.3324/haematol.2014.117077

DO - 10.3324/haematol.2014.117077

M3 - SCORING: Journal article

C2 - 26250580

VL - 100

SP - 1327

EP - 1333

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 10

ER -